<DOC>
	<DOCNO>NCT01854710</DOCNO>
	<brief_summary>It show pre-marketing clinical study clinically relevant QT prolongation appear associate single dose ADASUVE . The potential risk QTc prolongation follow repeat dose unknown . Therefore current study assess potential effect QT interval 2 consecutive dos ADASUVE administer 2 hour apart , relation placebo active control healthy volunteer . The study hypothesis H0 : Placebo-subtracted max mean dQTc &gt; 10 msec</brief_summary>
	<brief_title>QT/QTc Study 2 Doses ADASUVE®</brief_title>
	<detailed_description />
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Loxapine</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Male female subject age 18 65 year , inclusive . Body mass index ( BMI ) ≥18 ≤32 . Subjects willing able comply study schedule requirement , stay CRU 4day period 2 consecutive 3day period . Subjects speak , read , understand English and/or Dutch willing able provide write informed consent IEC approve form prior initiation study procedure . Subjects good general health prior study participation Female male participant agree use medically acceptable effective birth control method Subjects regularly consume large amount xanthinecontaining substance ( ≥ 5 cup coffee/day ) . Subjects take prescription nonprescription medication within 5 day Visit 2 . Subjects acute illness within last 5 day Visit 2 . Subjects smoke tobacco within last 30 day positive cotinine test . Subjects history HIV , antiHCV HbsAg positivity . Subjects history within past 2 year drug alcohol dependence abuse define DSMIV . Subjects test positive alcohol positive urine drug screen . Subjects history allergy intolerance loxapine amoxapine history bronchospasm follow inhaled loxapine treatment . Subjects ECG abnormality . Subjects hypotension , hypertension . Subjects history unstable angina , syncope , coronary artery disease , myocardial infarction , congestive heart failure , transient ischemic attack , history convulsion neurological disorder . Subjects current history asthma , chronic obstructive lung disease , lung disease associate bronchospasm . Subjects use medication treat airways disease , asthma COPD . Subjects acute respiratory signs/symptoms ( e.g. , wheeze ) . Female subject positive pregnancy test screen admission treatment visit , breastfeed . Subjects receive investigational drug within 60 day prior Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>ADASUVE</keyword>
	<keyword>inhaled loxapine</keyword>
	<keyword>thorough QT/QTc study</keyword>
</DOC>